Development and validation of a preclinical food effect model

Journal of Pharmaceutical Sciences

Volumn 96, Issue 2, 2007, Pages 459-472

  Lentz, Kimberley A ^a   Quitko, Megan ^a   Morgan, Daniel G ^a   Grace Jr , James E ^a   Gleason, Carol ^a   Marathe, Punit H ^a  

^a BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

Dog; Food effect; Model; Pentagastrin; Pharmacokinetics

Indexed keywords

ARIPIPRAZOLE; ATAZANAVIR; BLOOD CLOTTING FACTOR 10A INHIBITOR; CARBOHYDRATE; CELECOXIB; HALOFANTRINE; IRBESARTAN; LIPID; METFORMIN; PENTAGASTRIN; PRAVASTATIN; PROTEIN; RAVUCONAZOLE;

ANIMAL EXPERIMENT; ANIMAL FOOD; AREA UNDER THE CURVE; ARTICLE; CARBOHYDRATE DIET; DIET; DOG; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG FORMULATION; FOOD ANALYSIS; FOOD AVAILABILITY; FOOD DRUG INTERACTION; LIPID DIET; NONHUMAN; PHYSICAL CHEMISTRY; PREDICTION; PROTEIN DIET; QUALITATIVE ANALYSIS; TEST MEAL; VALIDATION PROCESS;

EID: 33847632169     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20767     Document Type: Article

References (45)

1. Fleisher D, Li C, Zhou Y, Pao LH, Karim A. 1999. Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications. Clin Pharmacokinet 36:233-254.
2. Yu LX, Straughn AB, Faustino PJ, Yang Y, Parekh A, Ciavarella AB, Asafu-Adjaye E, Mehta MU, Conner DP, Lesko LJ, Hussain AS. 2004. The effect of food on the relative bioavailability of rapidly dissolving immediate-release solid oral products containing highly soluble drugs. Mol Pharm 1:357-362.
3. Welling PG. 1989. Effects of food on drug absorption. Pharmacol Ther 43:425-441.
4. Charman WN, Porter CJ, Mithani S, Dressman JB. 1997. Physiochemical and physiological mechanisms for the effects of food on drug absorption: The role of lipids and pH. J Pharm Sci 86:269-282.
5. Maka DA, Murphy LK. 2000. Drug-nutrient interactions: A review. AACN Clin Issues 11:580-589.
6. Marathe PH, Greene DS, Kollia GD, Barbhaiya RH. 1998. Evaluation of the effect of food on the pharmacokinetics of avitriptan. Biopharm Drug Dispos 19:381-394.
7. FDA. 2002. Guidance for Industry: Food-Effect Bioavailability and Fed Bioequivalence Studies. Rockville, MD: Food and Drug Administration.
8. Wu CY, Benet LZ. 2005. Predicting drug disposition via application of BCS: Transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 22:11-23.
9. Amidon GL, Lennernas H, Shah VP, Crison JR. 1995. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413-420.
10. Reinoso RF, Farran R, Moragon T, Garcia-Soret A, Martinez L. 2001. Pharmacokinetics of E-6087, a new anti-inflammatory agent, in rats and dogs. Biopharm Drug Dispos 22:231-242.
11. 2004. Avapro (Bristol Myers Squibb) (irbesartan). Physicians Desk Reference (PDR), 58 ed. Montvale, NJ.
12. 2004. Abilify (Bristol Myers Squibb) (aripiprazole). Physicians Desk Reference (PDR), 58 ed. Montvale, NJ.
13. Cook CS, Hauswald CL, Grahn AY, Kowalski K, Karim A, Koch R, Schoenhard GL, Oppermann JA. 1990. Suitability of the dog as an animal model for evaluating theophylline absorption and food effects from different formulations. Int J Pharm 60:125-132.
14. Li C, Fleisher D, Li L, Schwier JR, Sweetana SA, Vasudevan V, Zornes LL, Pao LH, Zhou SY, Stratford RE. 2001. Regional-dependent intestinal absorption and meal composition effects on systemic availability of LY303366, a lipopeptide antifungal agent, in dogs. J Pharm Sci 90:47-57.
15. Humberstone AJ, Porter CJ, Charman WN. 1996. A physicochemical basis for the effect of food on the absolute oral bioavailability of halofantrine. J Pharm Sci 85:525-529.
16. Paulson SK, Vaughn MB, Jessen SM, Lawal Y, Gresk CJ, Yan B, Maziasz TJ, Cook CS, Karim A. 2001. Pharmacokinetics of celecoxib after oral administration in dogs and humans: Effect of food and site of absorption. J Pharmacol Exp Ther 297:638-645.
17. Lui CY, Amidon GL, Berardi RR, Fleisher D, Youngberg C, Dressman JB. 1986. Comparison of gastrointestinal pH in dogs and humans: Implications on the use of the beagle dog as a model for oral absorption in humans. J Pharm Sci 75:271-274.
18. Meyer JH, Dressman J, Fink A, Amidon G. 1985. Effect of size and density on canine gastric emptying of nondigestible solids. Gastroenterology 89:805-813.
19. Kondo H, Shinoda T, Nakashima H, Watanabe T, Yokohama S. 2003. Characteristics of the gastric pH profiles of unfed and fed cynomolgus monkeys as pharmaceutical product development subjects. Biopharm Drug Dispos 24:45-51.
20. Nicolaides E, Symillides M, Dressman JB, Reppas C. 2001. Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after oral administration. Pharm Res 18:380-388.
21. Nicolaides E, Galia E, Efthymiopoulos C, Dressman JB, Reppas C. 1999. Forecasting the in vivo performance of four low solubility drugs from their in vitro dissolution data. Pharm Res 16:1876-1882.
22. Dressman JB, Reppas C. 2000. In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. Eur J Pharm Sci 11:S73-S80.
23. FDA. 2000. Guidance for Industry: Waiver of On Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Dosage Forms Based on a Biopharmaceutics Classification System. Rockville, MD: Food and Drug Administration.
24. 2004. Attachment inhibitor may hold promise for future. BMS-488043 demonstrates safety. AIDS Alert 19:57-58.
25. De Clercq E. 2005. Emerging anti-HIV drugs. Expert Opin Emerg Drugs 10:241-273.
26. Hanna G, Yan J-H, Fiske W, Masterson T, Zhang D, Grasela D. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 8-11, 2004.
27. Weitz JI, Bates SM. 2005. New anticoagulants. J Thromb Haemost 3:1843-1853.
28. Fung-Tomc JC, Huczko E, Minassian B, Bonner DP. 1998. In vitro activity of a new oral triazole, BMS-207147 (ER-30346). Antimicrob Agents Chemother 42:313-318.
29. Tsuruoka A, Kaku Y, Kakinuma H, Tsukada I, Yanagisawa M, Nara K, Naito T. 1998. Synthesis and antifungal activity of novel thiazole-containing triazole antifungals. II. Optically active ER-30346 and its derivatives. Chem Pharm Bull (Tokyo) 46:623-630.
30. Arikan S, Rex JH. 2002. Ravuconazole Eisai/Bristol-Myers Squibb. Curr Opin Investig Drugs 3:555-561.
31. Ueda Y, Matiskella JD, Golik J, Connolly TP, Hudyma TW, Venkatesh S, Dali M, Kang SH, Barbour N, Tejwani R, Varia S, Knipe J, Zheng M, Mathew M, Mosure K, Clark J, Lamb L, Medin I, Gao Q, Huang S, Chen CP, Bronson JJ. 2003. Phosphonooxymethyl prodrugs of the broad spectrum antifungal azole, ravuconazole: Synthesis and biological properties. Bioorg Med Chem Lett 13:3669-3672.
32. Knupp CA, Shyu WC, Morgenthien EA, Lee JS, Barbhaiya RH. 1993. Biopharmaceutics of didanosine in humans and in a model for acid-labile drugs, the pentagastrin-pretreated dog. Pharm Res 10:1157-1164.
33. Wai KN, Gerring EE, Broad RD. 1970. Formulation and pharmacological studies of a controlled release pentagastrin injection. J Pharm Pharmacol 22:923-929.
34. Gibaldi M, Perrier D. 1982. Pharmacokinetics. 2nd ed. New York: Marcel Dekker.
35. SAS Institute Inc. 1999. SAS® Language: Reference, Language: Procedures Guide, and SAS/STAT® User's Guide. Version 8, Cary, NC: SAS Institute Inc.
36. Pan HY, DeVault AR, Brescia D, Willard DA, McGovern ME, Whigan DB, Ivashkiv E. 1993. Effect of food on pravastatin pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther Toxicol 31:291-294.
37. 2004. Reyataz (Bristol Myers Squibb) (atazanavir sulfate). Physicians Desk Reference (PDR). 58 ed. Montvale, NJ.
38. Akimoto M, Nagahata N, Furuya A, Fukushima K, Higuchi S, Suwa T. 2000. Gastric pH profiles of beagle dogs and their use as an alternative to human testing. Eur J Pharm Biopharm 49:99-102.
39. Kararli TT. 1995. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm Drug Dispos 16:351-380.
40. Zhou R, Moench P, Heran C, Lu X, Mathias N, Faria TN, Wall DA, Hussain MA, Smith RL, Sun D. 2005. pH-dependent dissolution in vitro and absorption in vivo of weakly basic drugs: Development of a canine model. Pharm Res 22:188-192.
41. Fotaki N, Symillides M, Reppas C. 2005. Canine versus in vitro data for predicting input profiles of L-sulpiride after oral administration. Eur J Pharm Sci 26:324-333.
42. Wu Y, Loper A, Landis E, Hettrick L, Novak L, Lynn K, Chen C, Thompson K, Higgins R, Batra U, Shelukar S, Kwei G, Storey D. 2004. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: A Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int J Pharm 285:135-146.
43. Charman WN, Rogge MC, Boddy AW, Berger BM. 1993. Effect of food and a monoglyceride emulsion formulation on danazol bioavailability. J Clin Pharmacol 33:381-386.
44. Internal Data. Princeton, NJ: Bristol Myers Squibb.
45. 2004. Metaglip (Bristol Myers Squibb) (glipizide and metformin HCl). Physicians Desk Reference (PDR), 58 ed. Montvale, NJ.